- Home
- OCUL
as 01-17-2025 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.4B | IPO Year: | 2014 |
| Target Price: | $16.50 | AVG Volume (30 days): | 874.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.76 - $11.78 | Next Earning Date: | 03-10-2025 |
| Revenue: | $61,442,000 | Revenue Growth: | 6.45% |
| Revenue Growth (this year): | 11.4% | Revenue Growth (next year): | 13.58% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nayak Sanjay | OCUL | Chief Strategy Officer | Nov 25 '24 | Sell | $9.00 | 1,814 | $16,326.00 | 174,380 | |
| Dugel Pravin | OCUL | See Remarks | Nov 25 '24 | Sell | $9.01 | 20,680 | $186,326.80 | 791,793 | |
| Kaiser Peter | OCUL | Chief Development Officer | Nov 25 '24 | Sell | $9.01 | 2,897 | $26,101.97 | 213,087 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Nov 25 '24 | Sell | $9.01 | 2,948 | $26,561.48 | 269,059 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 days ago
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
GlobeNewswire
10 days ago
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
Simply Wall St.
a month ago
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week
GlobeNewswire
a month ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TipRanks
2 months ago
Ocular Therapeutix announces over 300 subjects randomized in SOL-1
GlobeNewswire
2 months ago
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.